UIC researchers receive $10.15 million grant to develop treatment for dry eye conditions

Researchers at University of Illinois Chicago have been awarded a five-year, $10.15 million grant to develop a broad-spectrum immunomodulatory eye drop to treat patients with severe dry eye and ocular surface disease due to inflammatory and immune system disorders.

Dr. Sandeep Jain, a professor of ophthalmology at UIC's College of Medicine, is principal investigator. He received the grant from the National Eye Institute for a "Translational Research Program to Develop Novel Therapies and Devices for the Treatment of Visual System Disorders."

In the U.S., over 14% of the population over 50 experience dry eye, according to Jain. Dry eye can be caused by medical conditions including rheumatoid arthritis, lupus, thyroid disease, and sarcoidosis. Aging is also a common cause.

Currently, drugs approved to treat dry eye conditions affect the T-cell function and do not have any actions against pathogenic autoantibodies. Researchers plan to develop an antibody-based eye drop that contains pooled human immune globulins as an active ingredient, which have broad-spectrum immunomodulatory actions via anti-idiotypic, molecular and cellular mechanisms. The new eye drops are expected to be particularly helpful in patients who have dry eyes due to immune disorders.

The new grant will fund production of preclinical data that supports a commercial application to the U.S. Federal Drug Administration to enable testing the pooled human immune globulin eye drops in phased clinical trials.

Our hope is that we can improve the quality of life of patients who suffer greatly because of dry eyes due to inflammatory and immune system disorders because of lack of availability of effective therapies."

Dr. Sandeep Jain, Professor of Ophthalmology, UIC's College of Medicine

Jain's research experience includes key discoveries in dry eye conditions such as the presence of Neutrophil Extracellular Traps on the ocular surface of patients with dry eye disease and anti-citrullinated proteins and autoantibodies in the tears. He was the first to describe the use of pooled human immune globulin eye drops for treating dry eye patients.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents